Trial Profile

A Phase 1/2a Study of IMM-6-415 in Participants With Advanced or Metastatic Malignancies Harboring RAS or RAF Oncogenic Mutations

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 02 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IMM 6 415 (Primary)
Indications Adenocarcinoma; Gastrointestinal cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
Sponsors Immuneering

Most Recent Events

28 May 2025 Status changed from recruiting to completed.
12 Sep 2024 According to an Immuneering media release, initial pharmacokinetic (PK), pharmacodynamic (PD) and safety data from the Phase 1 portion of the Company's Phase 1/2a trial is expected by year end.
06 Aug 2024 According to an Immuneering media release, Initial pharmacokinetic (PK), pharmacodynamic (PD) and safety data expected in 2H 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com